

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 July 2021 (01.07.2021)



(10) International Publication Number
WO 2021/133976 A1

(51) International Patent Classification:

A01N 1/02 (2006.01) A61K 31/575 (2006.01)
A61K 31/568 (2006.01) C07J 31/00 (2006.01)

(21) International Application Number:

PCT/US2020/066947

(22) International Filing Date:

23 December 2020 (23.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/954,279 27 December 2019 (27.12.2019) US

(71) Applicant: DURECT CORPORATION [US/US]; 10260
Bubb Road, Cupertino, California 95014-4166 (US).

(72) Inventors: MIKSZTAL, Andrew; 743 Cereza Drive, Pa-
lo Alto, California 94306 (US). JOHNSTONE, Shawn;
1600 rue de Beauvoir, Saint-Lazare, Québec H8S1X1 (CA).
HOLTZ-MULHOLLAND, Michael; 1915 Rue Remem-

brance, Lachine, Québec H8S1X1 (CA). LOPEZ, Flavio;
101 Technology Place, Florence, South Carolina 29051
(US). SARD, Howard; 67 Hillside Ave., Arlington, Mass-
achusetts 02476 (US). LI, Jie; 103 Loring Ave, Win-
chester, Massachusetts 01890 (US). GONZALEZ, Mario;
17 Harvard St., Winchester, Massachusetts 01890 (US).
PARENT, Stephan D.; 1200 Fawn Ridge Dr., West
Lafayette, Indiana 47909 (US). HOUSTON, Travis Lee;
3240 Hendrickson Lane, Lafayette, Indiana 47909 (US).
WENSLOW, Robert; 3000 Eastpark Blvd., Suite 500B,
Cranbury, New Jersey 08512 (US).

(74) Agent: CHIN, Khin K.; BOZICEVIC, FIELD &
FRANCIS LLP, 201 Redwood Shores Parkway, Suite 200,
Redwood City, California 94065 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

(54) Title: CRYSTALLINE AND LIQUID CRYSTALLINE 25-HYDROXY-CHOLEST-5-EN-3-SULFATE SODIUM AND
METHODS FOR PREPARING SAME

Observed peaks for XRPD file 614894 collected with Cu-K α radiation.




Figure 1 – Form I XRPD Diffractogram

Output rendered using Triads™ v2.1

(57) Abstract: Crystalline and liquid crystalline forms of 25HC3S sodium are described herein. The disclosure includes Forms I, II, III, V, IX, XI, and XIII of 25HC3S sodium and combinations thereof. Pharmaceutical formulations of said forms, or combinations thereof, and methods of treating or preventing disease such as hypercholesterolemia, hypertriglyceridemia, and conditions related to fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis) are further disclosed herein. Methods for preparing 25HC3S are also provided

[Continued on next page]

WO 2021/133976 A1

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*